Gyeongsang National University, College of Natural Sciences, Research Institute of Life Science, Department of Microbiology, Jinju 660-701, Korea.
Expert Opin Ther Targets. 2010 Jan;14(1):67-75. doi: 10.1517/14728220903449251.
Rho GDP dissociation inhibitor 2 (RhoGDI2) has been identified as a regulator of Rho GTPases that play important roles in the development of numerous aspects of the malignant phenotype, including cell cycle progression, resistance to apoptotic stimuli, neovascularization, tumor cell motility, invasiveness, and metastasis. Although RhoGDI2 has been known to be expressed only in hematopoietic tissues, recent studies suggest that this protein is also aberrantly expressed in several human cancers and contributes to aggressive phenotypes, such as invasion and metastasis. Hence, RhoGDI2 appears to be a target of interest for therapeutic manipulation.
Here, we summarize the role of RhoGDI2 in human cancers, specifically metastasis-related processes, and discuss its potential as a therapeutic target.
RhoGDI2 modulates the invasiveness and metastatic ability of cancer cells through regulation of Rac1 activity.
RhoGDI2 may be a useful marker for tumor progression in human cancers, and interruption of the RhoGDI2-mediated cancer cell invasion and metastasis by an interfacial inhibitor may be a powerful therapeutic approach to cancer.
Rho GDP 解离抑制剂 2（RhoGDI2）已被确定为 Rho GTPases 的调节剂，Rho GTPases 在恶性表型的许多方面的发展中发挥重要作用，包括细胞周期进展、对凋亡刺激的抵抗、新血管生成、肿瘤细胞迁移、侵袭和转移。尽管已知 RhoGDI2 仅在造血组织中表达，但最近的研究表明，这种蛋白质也在几种人类癌症中异常表达，并有助于侵袭和转移等侵袭性表型。因此，RhoGDI2 似乎是治疗干预的一个有吸引力的目标。
在这里，我们总结了 RhoGDI2 在人类癌症中的作用，特别是与转移相关的过程，并讨论了它作为治疗靶点的潜力。
RhoGDI2 通过调节 Rac1 活性来调节癌细胞的侵袭和转移能力。
RhoGDI2 可能是人类癌症中肿瘤进展的有用标志物，通过界面抑制剂中断 RhoGDI2 介导的癌细胞侵袭和转移可能是一种有效的癌症治疗方法。
